All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Biopharmas raising money in public or private financings, including: Affimed, Aquestive, Blue Water, Crinetics, Liquidia, Lixte, Lyra, Navidea and NLS.
NEC Corp. subsidiary NEC Oncoimmunity AS recently received $4.8 million from the Coalition for Epidemic Preparedness Innovations to fund the development of vaccines for SARS-CoV-2 variants and other betacoronaviruses.
Biopharma financings for the first quarter of 2022 are at a five-year low, with 65.8% less money and 53% fewer transactions than a year ago. The industry raised $13.1 billion through 249 financings, compared with $38.3 billion from 529 transactions in 2021.
NEC Corp. subsidiary NEC Oncoimmunity AS recently received $4.8 million from the Coalition for Epidemic Preparedness Innovations to fund the development of vaccines for SARS-CoV-2 variants and other betacoronaviruses.
U.S. private equity group Carlyle is extending its reach into biotech financing through the acquisition of London-based venture capital firm Abingworth, with which it is forming Launch Therapeutics, an operating company that will fund and manage late-stage clinical development of programs sourced from pharma and biotech companies. The move will enable further scaling of the clinical co-development model Abingworth first devised in 2009.